**MARKET BRIEF: Accretion Nutraveda Lists with 48% Premium** **Stellar Debut Defies Tepid Subscription** Accretion Nutraveda Limited made a strong entrance on the BSE SME platform today (February 4, 2026). The stock opened at **₹191**, delivering a massive **48.06% premium** over its issue price of **₹129**. Momentum continued post-listing, with the price hitting the upper circuit at **₹200.55**, marking a **55.43%** gain intraday. **Subscription Recap** The robust listing contradicts the modest demand seen during the bidding phase. The IPO was subscribed just **1.83 times** overall. * **Retail:** Subscribed **2.19 times**. * **NII (Non-Institutional Investors):** Demand stood at **2.08 times**. * **QIB (Qualified Institutional Buyers):** Marginally covered at **1.01 times**. * **Anchor Book:** Raised **₹7.02 crore** prior to the public issue. **Valuation & Market Data** Following the surge, the company's market capitalization expanded to approximately **₹145 crore**, up from the pre-issue valuation of **₹93.4 crore**. The trading volume on Day 1 exceeded **6.3 lakh shares**, indicating aggressive buying despite the low float. **Company Profile** Accretion Nutraveda operates as a Contract Development and Manufacturing Organization (CDMO) based in Gujarat. It specializes in Ayurvedic and nutraceutical products, including tablets, capsules, and oils. The company exports to markets like the USA, Singapore, and Sri Lanka. **Financial Snapshot** * **FY25 Revenue:** **₹16.06 crore** (Tripled from FY24). * **FY25 Net Profit:** **₹2.61 crore**. * **Margins:** Documented healthy PAT margins of **~16%**. **Investor Note** The minimum investment for retail participants was **₹2.58 lakh** (2,000 shares), which has now appreciated significantly in value on listing day.